Clinical Trial

A Study of SEP-380135 in Adults With Schizophrenia or Major Depressive Episode

Name: A Study of SEP-380135 in Adults With Schizophrenia or Major Depressive Episode — clinical trial record (NCT07549581)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Completed Phase 1

View on ClinicalTrials.gov →

Summary

The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of multiple dose oral administration of SEP-380135 in participants with schizophrenia or with a major depressive episode associated with bipolar I or II disorder or major depressive disorder (MDD).

Trial Details

NCT Number	NCT07549581
Lead Sponsor	Otsuka Pharmaceutical Development & Commercialization, Inc.
Conditions	Schizophrenia, Major Depressive Disorder (MDD), Bipolar Disorder
Enrollment	43 participants
Start Date	2024-11-07
Primary Completion	2025-09-12 (estimated)
Study Completion	2025-09-12 (estimated)
Updated on ClinicalTrials.gov	2026-04-24